Posts Tagged ‘Joachim Greuel#8217;

September 1, 2011

Professor Greuel at the EPMA World Congress 2011

Written on September 1, 2011 by blended.team in News

Dr. Joachim Greuel Our Academic Director and Professor of Finance & Healthcare Management  Dr. Joachim Greuel,  will attend as one of the most renowed speakers at the EPMA World Congress 2011 in Bonn as part of the team of the specialised session “National and International Granting Strategies in PPPM: Innovative Programmes, Economy of Personalised Medicine”.

 

 The Congress will take place the 16th Sept 2011 at the Parliament of Federal Republic of Germany (Bundeshaus)

Parliament of Federal Republic of Germany

August 6, 2011

Reviews from the Industry by Joachim Greuel

Written on August 6, 2011 by blended.team in MBM News, News, Pharma Industry

Reviews from the Industry: Today, our academic director Joachim Greuel sets the focus on Biotech Stocks and the relevance of pricing decisions in the Companies.

 Biotech Stocks Vulnerable to Economic Concerns 

Biotech Stocks

 Last Thursday, 4 August 2011 the NASDAQ Biotechnology and the AMEX Biotechnology indices lost 8% and 11%, respectively, while the AMEX Pharmaceutical index fell only 4%. The last time a similar downturn was observed was in 2008.

This demonstrates, once more, that biotech stocks with highly volatile cash flows are more vulnerable to the general economic environment than stocks of more established firms.

While this may not come as a surprise, some biotech companies suffer more from general market conditions than others.

As a consequence, management should design strategies to minimize volatility as much as possible, also in order to reduce its cost of capital.

 In our MBM courses we will discuss strategies how this may be accomplished.

Dendreon Falls 67% After Lower Than Expected Provenge Sales

Dendreon Case

 Last  Thursday, 4 August 2011, Dendreon stock fell 67% (by $24.15 to $11.69) after the company reported a lower than expected uptake of its recently (April 2010) approved cancer cell therapy Provenge.

As Provenge is the first available autologous cellular immunotherapy against cancer worldwide, the stock has received significant attention. It is believed that the therapy’s high price prevents a rapid market penetration. Although the US federal agency CMS has determined that Medicare will reimburse the therapy that costs over $90,000.-, the therapy’s cost-effectiveness has been questioned as it extends life by no more than four months, on average.

The Dendreon case demonstrates the importance of  pricing decisions: innovative therapies that do not demonstrate a clear cost-effectiveness will penetrate the market much slower than they would with a shown, undisputable pharmacoeconomic benefit. Thus, pricing decisions are no longer solely driven by market studies such as conjoint analyses, but also by outcomes research. Biotech managers that often tend to focus on R&D should think about pharmacoeconomics; the likelihood of a good licensing deal, for example, also depends on pharmacoeconomic aspects 

July 8, 2011

Meet the new Academic Director!

Written on July 8, 2011 by blended.team in MBM News

Joachim Greuel, Phd and MBA, is the new Academic Director for the Master in Biotechnology Management.

Joachim Greuel is founding and managing partner of Bioscience Valuation in Germany. The firm supports private and public biotech companies worldwide to communicate their value propositions and to close financial transactions successfully. He is also Co-founder of BioCapital Advisors, a company recently founded in Madrid, focusing on the evaluation and marketing of healthcare investment opportunities.
Joachim began his professional career as head of a research team at Bayer AG (Germany). After his business education he joined the strategic services practice of Andersen Consulting (Switzerland and Germany). Before founding Bioscience Valuation Joachim was investment manager at New Medical Technologies, a Swiss venture capital fund.

Joachim studied biology in Marburg (Germany) and Cambridge (UK) and received his Ph.D. summa cum laude from the Max Planck Institute for Brain Research in Frankfurt (Germany). He holds an MBA with a finance and health care focus from the Wharton School of the University of Pennsylvania (USA). Joachim is a member of the ‘American Finance Association’ and a number of professional healthcare organizations.

We use both our own and third-party cookies to enhance our services and to offer you the content that most suits your preferences by analysing your browsing habits. Your continued use of the site means that you accept these cookies. You may change your settings and obtain more information here. Accept